DE69130950D1 - Krebsassoziierter erkennungsfaktor-scm, seine herstellung und gebrauchsverfahren - Google Patents

Krebsassoziierter erkennungsfaktor-scm, seine herstellung und gebrauchsverfahren

Info

Publication number
DE69130950D1
DE69130950D1 DE69130950T DE69130950T DE69130950D1 DE 69130950 D1 DE69130950 D1 DE 69130950D1 DE 69130950 T DE69130950 T DE 69130950T DE 69130950 T DE69130950 T DE 69130950T DE 69130950 D1 DE69130950 D1 DE 69130950D1
Authority
DE
Germany
Prior art keywords
scm
factor
cancer
useful
scm factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69130950T
Other languages
English (en)
Inventor
Boris Cercek
Lea Cercek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69130950D1 publication Critical patent/DE69130950D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4745—Cancer-associated SCM-recognition factor, CRISPP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
DE69130950T 1990-06-18 1991-06-18 Krebsassoziierter erkennungsfaktor-scm, seine herstellung und gebrauchsverfahren Expired - Lifetime DE69130950D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/539,686 US5270171A (en) 1987-03-06 1990-06-18 Cancer-associated SCM-recognition factor, preparation and method of use
PCT/US1991/004334 WO1991019736A2 (en) 1990-06-18 1991-06-18 Cancer-associated scm-recognition factor, preparation and method of use

Publications (1)

Publication Number Publication Date
DE69130950D1 true DE69130950D1 (de) 1999-04-08

Family

ID=24152242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130950T Expired - Lifetime DE69130950D1 (de) 1990-06-18 1991-06-18 Krebsassoziierter erkennungsfaktor-scm, seine herstellung und gebrauchsverfahren

Country Status (11)

Country Link
US (2) US5270171A (de)
EP (1) EP0537276B1 (de)
JP (1) JPH05509308A (de)
KR (1) KR930700536A (de)
AT (1) ATE177116T1 (de)
AU (1) AU665337B2 (de)
CA (1) CA2084767A1 (de)
DE (1) DE69130950D1 (de)
FI (1) FI925736A (de)
IL (1) IL98455A (de)
WO (1) WO1991019736A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
JPH08500107A (ja) * 1992-08-10 1996-01-09 サーセック、ボリス 癌関連ｓｃｍ認識因子の免疫化学的検定
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
AU1867397A (en) 1995-11-16 1997-06-05 Michael W. Dahm Method of quantifying tumour cells in a body fluid and a suitable test kit
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
DE19804372A1 (de) 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
DE19904267A1 (de) * 1999-02-03 2000-08-10 Michael W Dahm Verfahren zur Anreicherung von Tumorzellen aus einer Körperflüssigkeit und dazu geeigneter Kit
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
WO2003038432A1 (en) * 2001-07-13 2003-05-08 Curagen Corporation Chi square tests for gene expression
EP1679083A3 (de) * 2002-06-21 2006-08-02 Edwin L. Adair Anwendung von Metalloporphyrinen zur Behandlung von Arteriosklerose
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
US8208142B2 (en) * 2003-12-24 2012-06-26 King Salid University Lung cancer detection by optical analysis of body fluids
US7869033B2 (en) * 2003-12-24 2011-01-11 Vadivel Masilamani Cancer detection by optical analysis of body fluids
US7264794B2 (en) * 2004-12-17 2007-09-04 The General Hospital Methods of in vivo cytometry
US7491502B2 (en) * 2004-12-17 2009-02-17 The General Hospital Corporation In vivo flow cytometry system and method
US7288098B2 (en) 2005-04-14 2007-10-30 Ethicon Endo-Surgery, Inc. Force limiting mechanism for medical instrument
US7297149B2 (en) 2005-04-14 2007-11-20 Ethicon Endo-Surgery, Inc. Surgical clip applier methods
US8038686B2 (en) 2005-04-14 2011-10-18 Ethicon Endo-Surgery, Inc. Clip applier configured to prevent clip fallout
US7686820B2 (en) 2005-04-14 2010-03-30 Ethicon Endo-Surgery, Inc. Surgical clip applier ratchet mechanism
US7740641B2 (en) 2005-04-14 2010-06-22 Ethicon Endo-Surgery, Inc. Clip applier with migrational resistance features
US7261724B2 (en) 2005-04-14 2007-08-28 Ethicon Endo-Surgery, Inc. Surgical clip advancement mechanism
US8523882B2 (en) 2005-04-14 2013-09-03 Ethicon Endo-Surgery, Inc. Clip advancer mechanism with alignment features
US20110060232A1 (en) * 2007-05-04 2011-03-10 The General Hospital Corporation Retinal flow cytometry
US8574859B2 (en) * 2008-03-27 2013-11-05 The General Hospital Corporation In vivo flow cytometry based on cellular autofluorescence
US8267945B2 (en) 2009-10-09 2012-09-18 Ethicon Endo-Surgery, Inc. Clip advancer with lockout mechanism
US8262679B2 (en) 2009-10-09 2012-09-11 Ethicon Endo-Surgery, Inc. Clip advancer
US9370400B2 (en) 2011-10-19 2016-06-21 Ethicon Endo-Surgery, Inc. Clip applier adapted for use with a surgical robot
ITRM20120028A1 (it) * 2012-01-25 2013-07-26 Natalia Malara Metodo per isolare cellule tumorali circolanti.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001080A (en) * 1972-10-20 1977-01-04 Piktor Limited Production of immunological materials
SU445690A1 (ru) * 1973-06-04 1974-10-05 Витебский государственный медицинский институт Способ определени сенсибилизации лейкоцитов
IL57135A (en) * 1979-04-25 1982-12-31 Abic Project Partnership Method for the determination of a factor or factors which enhances the cortisol metabolism in lymphocytes or leucocytes
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3333752A1 (de) * 1983-09-19 1985-04-11 Victor Dipl.- Chem. 8000 München Brantl Pharmakologisch aktive peptide
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4701406A (en) * 1984-11-16 1987-10-20 Trustees Of Boston University Assay for the detection of epigenetic toxic (non-genotoxic) substances
EP0272291B1 (de) * 1986-05-27 1992-04-01 CERCEK, Boris Verfahren zur messung polarisierter fluoreszenzemission
DE3872235T2 (de) * 1987-03-06 1992-12-03 Boris Cercek Allgemeiner krebsverbundener faktor, durch scm erkannt, seine praeparation und sein verwendungsverfahren.
WO1989008118A1 (en) * 1988-03-02 1989-09-08 Boris Cercek Synthetic scm-active cancer recognition peptides
WO1989008662A1 (en) * 1988-03-11 1989-09-21 Boris Cercek General cancer-associated scm-recognition factor, preparation and method of use
DE68926121T2 (de) * 1988-10-21 1996-10-17 Boris Cercek Präparat von blutzellen spezifischer dichte für den scm-test

Also Published As

Publication number Publication date
US5270171A (en) 1993-12-14
EP0537276B1 (de) 1999-03-03
EP0537276A1 (de) 1993-04-21
FI925736A0 (fi) 1992-12-17
IL98455A (en) 1997-01-10
WO1991019736A3 (en) 1992-02-20
FI925736A (fi) 1992-12-17
AU8287791A (en) 1992-01-07
ATE177116T1 (de) 1999-03-15
WO1991019736A2 (en) 1991-12-26
KR930700536A (ko) 1993-03-15
IL98455A0 (en) 1992-07-15
CA2084767A1 (en) 1991-12-19
US5443967A (en) 1995-08-22
AU665337B2 (en) 1996-01-04
JPH05509308A (ja) 1993-12-22

Similar Documents

Publication Publication Date Title
DE69130950D1 (de) Krebsassoziierter erkennungsfaktor-scm, seine herstellung und gebrauchsverfahren
Dy et al. Histamine production during the anti-allograft response. Demonstration of a new lymphokine enhancing histamine synthesis
Hollinshead et al. Separation of skin reactive intestinal cancer antigen from the carcinoembryonic antigen of Gold
Chadwick et al. Fluorescent protein tracers: a trial of new fluorochromes and the development of an alternative to fluorescein
Breckler et al. Isolation of a new high molecular weight protein associated with desmin and vimentin filaments from avian embryonic skeletal muscle
Amirante Production of heteroagglutinins in haemocytes of Leucophaea maderae L.
Burger et al. Human transfer factor: Effects on lymphocyte transformation
Laufer Immunochemical studies of muscle proteins in mature and regenerating limbs of the adult newt, Triturus viridescens
Norris et al. Systematic comparison of antibody-mediated mechanisms of keratinocyte lysis in vitro.
Nathenson et al. Biochemical similarity of papain-solubilized H-2d alloantigens from tumor cells and from normal cells
Geller et al. Electrophoresis of saliva
Thomas et al. The separation of human B lymphocytes on a digestible immunoadsorbent column
Aarli Binding of γ-globulin fragments to muscle tissue
Cercek et al. Induction of PHA response in mouse bone marrow cells by thymic extracts as studied by changes in the structuredness of cytoplasmic matrix.
NO924844L (no) Cancerassosiert scm-gjenkjennelsesfaktor, fremgangsmaate for dens fremstilling og anvendelse av faktoren
Yoshino Surface antigens of Biomphalaria glabrata (Gastropoda) hemocytes: occurrence of membrane-associated hemolymph-like factors antigenically related to snail hemoglobin
AU624071B2 (en) General cancer-associated scm-recognition factor, preparation and method of use
Krasnow et al. Membrane proteins synthesized by human reticulocytes and their precursors
Reiss et al. Fixation of complement to fragments of antibody
Riesz et al. Determination of free radicals in gamma irradiated proteins
Høyeraal Granulocyte reactive antinuclear factors in juvenile rheumatoid arthritis
Grdina Separation of Clonogenic Cells from Stationary Phase Cultures and a Murine Fibrosarcoma by Density-Gradient Centrifugation
Abandowttz et al. Immunochemical characteristics of rat skeletal muscle myosin
Rosen et al. Tritium labelling of antibodies
Froussard et al. Histone variant composition of normal and leukaemic human lymphocytes: Analysis by gel electrophoresis of whole cells and nuclei

Legal Events

Date Code Title Description
8332 No legal effect for de